Coronary spasm and thrombosis in a bodybuilder using a nutritional supplement containing synephrine, octopamine, tyramine and caffeine by Smedema, J. P. & Muller, G. J.
May 2008, Vol. 98, No. 5  SAMJ
SCIENTIFIC LETTERS
372
14.    Lin JL, Lin-tan DT, Chen KH, et al. Repeat pulse of methylprednisolone and 
cyclophosphamide with continuous dexamethasone therapy for patients with severe 
paraquat poisoning. Crit Care Med 2006; 34(2): 368-373.
15.    Lin NC, Lin JL, Lin-Tan DT. Combined initial cyclophosphamide with repeated 
methylprednisolone pulse therapy for severe paraquat poisoning from dermal exposure.  
J Toxicol Clin Toxicol 2003; 41(6): 877-881.
16.    Buckley NA. Pulse corticosteroids and cyclophosphamide in paraquat poisoning. (Comment.) 
Am J Respir Crit Care Med 2001; 163(2): 585.
17.    Ikeda K, Kumagai Y, Nagano Y. Change in concentration of Vitamins C and E in rat tissues by 
paraquat administration. Biosci Biotechnol Biochem 2003; 76(5): 1130-1131.
18.    Osakada F, Hashino A, Kume T. Neuroprotective effects of alpha-tocopherol on oxidative 
stress in rat striatal cultures. Europ J Pharmacol 2003; 465: 15-22.
Accepted 3 December 2007.
Coronary spasm and thrombosis in a bodybuilder using a 
nutritional supplement containing synephrine, octopamine, 
tyramine and caffeine
J P Smedema, G J Müller
To the Editor: A young, previously healthy bodybuilder 
suffered an acute myocardial infarction in the absence 
of known cardiovascular risk factors or demonstrable 
atherosclerotic plaque. The infarction probably resulted from 
coronary spasm, platelet activation and in situ thrombosis 
triggered by the chronic consumption of a ‘nutritional 
supplement’ which contains synephrine, octopamine, tyramine 
and caffeine.
The 39-year-old bodybuilder presented after developing 
new-onset angina pectoris with vegetative symptoms 
during a bodybuilding competition. He had no previous 
medical history or cardiovascular risk factors, and denied 
ever using androgenic anabolic steroids. He had been 
involved in competitive bodybuilding for 7 years. He had 
been taking for several years a ‘nutritional supplement’ 
that contains synephrine (oxedrine), octopamine, tyramine 
(sympathomimetic amines) and caffeine. The preparation 
also contains several ‘nutrients’, of which the herb St John’s 
wort has significant pharmacological actions on the nervous 
system.1 In the 3 months preceding the competition concerned, 
he had taken a daily dose equivalent to 40 mg synephrine, 
400 mg caffeine, and an unspecified amount of tyramine 
and octopamine. Synephrine is more potent than the other 
sympathomimetic amines. Its action is similar to that of 
phenylephrine, an alpha-adrenergic agonist,2 and it has been 
used for treating hypotension in doses of about 100 mg 3 times 
a day. Octopamine has about one-hundredth the potency of 
noradrenaline. 
The patient had restricted his fluid intake and increased 
his carbohydrate intake during the 36 hours before the 
competition. Physical examination was normal. The 
electrocardiogram showed a wide right bundle-branch block 
that resolved after several hours, and 1 mm ST-segment 
elevation in leads II, III, aVF, and V4-6. There was evidence 
of renal impairment, with creatinine at 171 μmol/l and 
urea at 11 mmol/l, and creatine kinase (CK) levels of 8 500 
IU/l. The troponin T level was normal on admission, but 
rose to 0.53 ng/ml after 6 hours, and 1.9 ng/ml after 24 
hours. Echocardiography demonstrated a dyskinetic basal 
interventricular septum, with mild biventricular hypertrophy. 
Oral aspirin, clopidogrel and bisoprolol and intravenous 
nitroglycerine, enoxiparine and eptifibatide were initiated, 
and he was hydrated with intravenous 0.9% saline. Coronary 
angiography showed a thrombus in the proximal left anterior 
descending artery, with diffuse spasm in the mid- and distal 
segments (Fig. 1), which resolved after the administration 
of intracoronary nitroglycerine. A 4.5 mm bare metal stent 
covering the lesion was successfully positioned. His low-
density lipoprotein, high-density lipoprotein and triglyceride 
levels were respectively 2.1, 0.31 and 1 mmol/l, the fasting 
homocysteine level was normal, and anti-phospholipid 
antibodies were absent. He was discharged fully recovered and 
remains symptom-free 6 months later.
Discussion
The acute myocardial infarction in this young, previously 
healthy bodybuilder in the absence of known cardiovascular 
risk factors or demonstrable atherosclerotic plaque was 
probably caused by coronary spasm, platelet activation and in 
situ thrombosis.
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The USA’s Food and Drug Administration (FDA) banned 
the sale of products containing ephedrine alkaloids in 2004 
because of associated cardiovascular toxicity.3 Synephrine and 
octopamine are structurally similar to norepinephrine, and 
have been associated with acute myocardial infarction and 
ischaemic colitis. 4-7 Both are trace endogenous bioamines, 
agonists of the α1, α2, β1 and β3 adrenoreceptors, are found 
in human plasma, platelets, sympathic nerves and adrenal 
tissue, and are present in Citrus aurantium (Seville orange, 
bitter orange), an ingredient in dietary supplements marketed 
for weight loss.8-10 In animal studies, synephrine increased 
cardiac output and caused vasoconstriction and ventricular 
arrhythmias.11,12 Bitter orange has been identified as a cause 
of resistant hypertension, syncope, myocardial infarction, 
tachycardia and ventricular fibrillation, and exacerbated 
coronary spasm in tobacco smokers.5 Prolonged administration, 
or the combined consumption, of synephrine with octopamine 
and caffeine may result in haemodynamic effects.13-16 A single 
dose of bitter orange extract containing the equivalent of  
50 mg synephrine significantly increased the systolic and 
diastolic blood pressures, as well as the heart rate, of healthy 
young adults for up to 5 hours.17
The risk of adverse cardiovascular events may be higher in 
persons with pre-existing underlying cardiovascular disease. 
Caffeine enhances the cardiovascular and central nervous 
system effects of adrenergic amines though augmentation 
of catecholamine release.18-20 The enhanced sympathetic 
activity increases platelet reactivity. Although an underlying 
atheromatous plaque has not been excluded with absolute 
certainty in our patient, it seems very likely that use of a 
nutritional supplement containing synephrine, octopamine, 
tyramine and caffeine, combined with intravascular 
dehydration and impaired renal function, triggered coronary 
spasm and thrombosis of a major proximal coronary artery. 
Constituents of St John’s wort are inhibitors of serotonin, 
noradrenaline and dopamine uptake in the synaptic cleft,1 
which may potentiate the effects of alpha-adrenergic stimulants 
and thereby enhance their vasoconstrictor activities.
The safety of over-the-counter supplements containing 
synephrine has been called into question.4-8 Consumers 
consider dietary supplements to be safe, but these are 
currently not subjected to scientific scrutiny, and some contain 
potentially harmful ingredients. The use of supplements 
containing the combination of synephrine, octopamine, 
tyramine and caffeine may constitute a risk of cardiovascular 
toxicity. There is a need for centralised monitoring of clinical 
adverse events in consumers using nutritional supplements.
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
Fig. 1. Diagnostic coronary angiogram (postero-anterior view), demon-
strating thrombus in the proximal left anterior descending coronary artery 
(arrow), and diffuse spasm of the mid and distal segments of the vessel 
(arrowheads).
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